Quick-start HIV treatment switch for newcomers to Quebec
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study tests a faster way to switch to a modern HIV medication (Biktarvy) in people who have recently moved to Quebec and are already on HIV treatment. The goal is to see if this quick switch helps keep the virus under control with fewer clinic visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and living with HIV (type 1).
- You must have arrived in Quebec from another country or province within the last 2 years.
- This is your first visit ever to the study clinic.
- You have taken HIV medication in the past or are currently on it.
- You were born outside of Canada.
- If you are female at birth and could become pregnant, you must have a negative pregnancy test and agree not to get pregnant for one year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This study tests whether people with both HIV and hepatitis B (HBV) can safely stop or switch parts of their antiviral treatment. It aims to see if simpler treatment can keep both viruses under control for 96 weeks.
This study follows adults with well-controlled HIV who are planning to switch to a long-acting HIV medicine given as injections. It may help researchers understand how this approach works for people already stable on current treatment.
This study tests whether switching to a simpler, two-drug HIV pill (dolutegravir/lamivudine) is as safe and effective as staying on a three-drug regimen. It is for people whose HIV is already well-controlled and who are currently taking Biktarvy or Triumeq.
This study tests a newer HIV medication, B/F/TAF, as a first-line treatment. It compares B/F/TAF with older combinations (TDF+3TC+EFV or DTG/3TC) to see how well it works for people who have never taken HIV meds.
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.